Regional Differences in the Phase III Meteor Study of Cabozantinib (CABO) Versus Everolimus (EVE) in Advanced Renal Cell Carcinoma (RCC)

被引：0
|
作者：
Mainwaring, Paul [1 ]
Tannir, Nizar M. [1 ]
Powles, Thomas [1 ]
Motzer, Robert J. [1 ]
Rolland, Frederic [1 ]
Gravis, Gwanaelle [1 ]
Staehler, Michael [1 ]
Rink, Michael [1 ]
Retz, Margitta [1 ]
Csoszi, Tibor [1 ]
McCaffrey, John A. [1 ]
De Giorgi, Ugo [1 ]
Caserta, Claudia [1 ]
Cheporov, Sergey [1 ]
Gonzalez, Emilio Esteban [1 ]
Duran, Ignacio [1 ]
Larkin, James G. [1 ]
Berg, William [1 ]
Clary, Douglas O. [1 ]
Escudier, Bernard [1 ]
Choueiri, Toni K. [1 ]
机构：
[1] Mater Med Ctr, ICON Canc Care, South Brisbane, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
183
引用
收藏
页码：129 / 130
页数：2
相关论文
共 50 条
  • [21] Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
    Powles, Thomas
    Motzer, Robert J.
    Escudier, Bernard
    Par, Sumanta
    Kollmannsberger, Christian
    Pikiel, Joanna
    Gurney, Howard
    Rha, Sun Young
    Park, Se Hoon
    Geertsen, Poul F.
    Gross-Goupil, Marine
    Grande, Enrique
    Suarez, Cristina
    Markby, David W.
    Arroyo, Alan
    Dean, Mark
    Choueiri, Toni K.
    George, Daniel
    BRITISH JOURNAL OF CANCER, 2018, 119 (06) : 663 - 669
  • [22] Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
    Thomas Powles
    Robert J. Motzer
    Bernard Escudier
    Sumanta Pal
    Christian Kollmannsberger
    Joanna Pikiel
    Howard Gurney
    Sun Young Rha
    Se Hoon Park
    Poul F. Geertsen
    Marine Gross-Goupil
    Enrique Grande
    Cristina Suarez
    David W. Markby
    Alan Arroyo
    Mark Dean
    Toni K. Choueiri
    Daniel George
    British Journal of Cancer, 2018, 119 : 663 - 669
  • [23] Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
    Choueiri, T. K.
    Escudier, B.
    Powles, T.
    Mainwaring, P. N.
    Rini, B. I.
    Donskov, F.
    Hammers, H.
    Hutson, T. E.
    Lee, J-L
    Peltola, K.
    Roth, B. J.
    Bjarnason, G. A.
    Geczi, L.
    Keam, B.
    Maroto, P.
    Heng, D. Y. C.
    Schmidinger, M.
    Kantoff, P. W.
    Borgman-Hagey, A.
    Hessel, C.
    Scheffold, C.
    Schwab, G. M.
    Tannir, N. M.
    Motzer, R. J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19): : 1814 - 1823
  • [24] Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial
    Cella, David
    Escudier, Bernard
    Tannir, Nizar M.
    Powles, Thomas
    Donskov, Frede
    Peltola, Katriina
    Schmidinger, Manuela
    Heng, Daniel Y. C.
    Mainwaring, Paul N.
    Hammers, Hans J.
    Lee, Jae Lyun
    Roth, Bruce J.
    Marteau, Florence
    Williams, Paul
    Baer, John
    Mangeshkar, Milan
    Scheffold, Christian
    Hutson, Thomas E.
    Pal, Sumanta
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 757 - +
  • [25] Evaluation of the novel "trial within a trial" design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC)
    Hessel, C.
    Mangeshkar, M.
    Motzer, R. J.
    Escudier, B.
    Powles, T. B.
    Schwab, G.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [26] Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR?
    Ciccarese, Chiara
    Massari, Francesco
    Tortora, Giampaolo
    EUROPEAN UROLOGY, 2016, 69 (05) : 969 - 970
  • [27] Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)
    Powles, T.
    Motzer, R. J.
    George, D. J.
    Jonasch, E.
    Pal, S.
    Tannir, N. M.
    Signoretti, S.
    Mai, T. H.
    Scheffold, C.
    Wang, E.
    Aftab, D. T.
    Escudier, B.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (RCC)
    Gruellich, C.
    Powles, T.
    Motzer, R. J.
    George, D. J.
    Jonasch, E.
    Pal, S. K.
    Tannir, N. M.
    Signoretti, S.
    Mai, T. H.
    Scheffold, C.
    Wang, E.
    Aftab, D. T.
    Escudier, B. J.
    Choueiri, T. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 201 - 201
  • [29] Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma
    Tannir, Nizar M.
    Powles, Thomas
    Escudier, Bernard
    Donskov, Frede
    Gruenwald, Viktor
    Sternberg, Cora N.
    Schmidinger, Manuela
    Schoeffski, Patrick
    Szczylik, Cezary
    Peltolta, Katriina
    Nosov, Dmitry
    Melichar, Bohuslav
    Clary, Douglas
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    KIDNEY CANCER, 2020, 4 (01) : 29 - 39
  • [30] Efficacy of cabozantinib vs everolimus in advanced renal cell carcinoma with bone metastases: results from the phase 3 METEOR study
    Bracarda, S.
    Choueiri, T. K.
    Powles, T.
    Motzer, R. J.
    Olencki, T.
    Frontera, O. A.
    Oudard, S.
    Rolland, F.
    Tomczak, P.
    Castellano, D.
    Appleman, L.
    Drabkin, H.
    Vaena, D.
    Milwee, S.
    Youkstetter, J.
    Escudier, B.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S196 - S196
12345